Whaley-Connell Adam, Sowers James R, McCullough Peter A, Roberts Tricia, McFarlane Samy I, Chen Shu-Cheng, Li Suying, Wang Changchun, Collins Allan J, Bakris George L
Department of Internal Medicine, University of Missouri-Columbia School of Medicine and Harry S. Truman VA Medical Center, Columbia, MO 65212, USA.
Am J Kidney Dis. 2009 Apr;53(4 Suppl 4):S11-21. doi: 10.1053/j.ajkd.2009.01.004.
Diabetes contributes to increased morbidity and mortality in patients with chronic kidney disease (CKD). We sought to describe CKD awareness and identify factors associated with optimal glycemic control in diabetic and nondiabetic individuals both aware and unaware of CKD.
This cross-sectional analysis compared Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999 to 2006 participants with diabetes and CKD. CKD was defined and staged using glomerular filtration rate (estimated by using the 4-variable Modification of Diet in Renal Disease Study equation) and urine albumin-creatinine ratio. NHANES defined diabetes as self-reported diabetes or fasting plasma blood glucose level of 126 mg/dL or greater, and KEEP as self-reported diabetes or diabetic retinopathy, use of diabetes medications, fasting blood glucose level of 126 mg/dL or greater, or nonfasting glucose level of 200 mg/dL or greater.
Of 77,077 KEEP participants, 20,200 (26.2%) were identified with CKD and 23,082 (29.9%) were identified with diabetes. Of 9,536 NHANES participants, 1,743 (18.3%) were identified with CKD and 1,127 (11.8%) were identified with diabetes. Of KEEP participants with diabetes and CKD (n = 7,853), 736 (9.4%) were aware of CKD. Trends in lack of CKD awareness were similar for KEEP participants with and without diabetes. Unaware participants with and without diabetes identified with stages 1 and 2 CKD were less likely to reach target glucose levels, defined as fasting glucose level less than 126 mg/dL or nonfasting glucose level less than 140 mg/dL, than those with stages 3 to 5 (odds ratio, 0.69; 95% confidence interval, 0.62 to 0.78; odds ratio, 0.69; 95% confidence interval, 0.58 to 0.81; P < 0.001, respectively).
Our data support that KEEP, as a targeted screening program, is a more enriched population with CKD and comorbid diabetes than NHANES. In addition, our findings highlight the relationship between dysglycemia and early stages of unidentified CKD.
糖尿病会导致慢性肾脏病(CKD)患者的发病率和死亡率增加。我们试图描述CKD的知晓情况,并确定在知晓和不知晓CKD的糖尿病和非糖尿病个体中与最佳血糖控制相关的因素。
这项横断面分析比较了1999年至2006年参加肾脏早期评估项目(KEEP)和国家健康与营养检查调查(NHANES)的糖尿病和CKD患者。CKD通过肾小球滤过率(使用肾脏疾病饮食改良研究方程的四变量估算)和尿白蛋白肌酐比值进行定义和分期。NHANES将糖尿病定义为自我报告的糖尿病或空腹血糖水平≥126mg/dL,KEEP将糖尿病定义为自我报告的糖尿病或糖尿病视网膜病变、使用糖尿病药物、空腹血糖水平≥126mg/dL或非空腹血糖水平≥200mg/dL。
在77,077名KEEP参与者中,20,200名(26.2%)被确诊患有CKD,23,082名(29.9%)被确诊患有糖尿病。在9,536名NHANES参与者中,1,743名(18.3%)被确诊患有CKD,1,127名(11.8%)被确诊患有糖尿病。在患有糖尿病和CKD的KEEP参与者(n = 7,853)中,736名(9.4%)知晓CKD。患有和未患有糖尿病的KEEP参与者中,缺乏CKD知晓的趋势相似。与3至5期患者相比,1至2期未被诊断出CKD的糖尿病和非糖尿病患者达到目标血糖水平(定义为空腹血糖水平<126mg/dL或非空腹血糖水平<140mg/dL)的可能性较小(优势比分别为0.69;95%置信区间为0.62至0.78;优势比为0.69;95%置信区间为0.58至0.81;P<0.001)。
我们的数据支持,作为一项针对性筛查项目,KEEP中患有CKD和合并糖尿病的人群比NHANES中的人群更具代表性。此外,我们的研究结果突出了血糖异常与未被识别的CKD早期阶段之间的关系。